Search

A recent study from Seoul National University Children's Hospital highlights the challenges in diagnosing lupus nephritis (LN) due to overlapping symptoms with other conditions like immunoglobulin A nephropathy (IgAN). The case report discusses a pediatric patient initially misdiagnosed with IgAN, later found to have LN with lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS). The study emphasizes the importance of clinical suspicion, integrating various data, and considering LAHPS in the differential diagnosis of glomerulonephritis with coagulopathy. [Extracted from the article]

Researchers from Duke University Medical Center have conducted a study on engineering immunogens to select for specific mutations in HIV broadly neutralizing antibodies. The research aims to design HIV vaccines that induce broadly neutralizing antibodies with conserved paratopes and mutations. By using molecular dynamics simulations, the researchers identified Env mutations that can select for desired antibody mutations in vivo, demonstrating the feasibility of designing sequential bnAb-inducing HIV-1 vaccines. This study provides valuable insights into vaccine development targeting rapidly evolving pathogens like HIV-1. [Extracted from the article]

Researchers have submitted a patent application for a new vaccine aimed at preventing Hepatitis C Virus (HCV) infection. The vaccine, which contains nucleoside-modified mRNA-lipid nanoparticles, targets specific HCV antigens to induce an immune response in subjects. This development is crucial due to the significant clinical burden of HCV infection worldwide and the limitations of current treatment options. The vaccine aims to address the urgent need for prophylactic and therapeutic solutions for HCV. [Extracted from the article]

A recent study conducted by researchers at the National Institute for Public Health and the Environment focused on the long-term dynamics of measles virus-specific neutralizing antibodies in children vaccinated before 12 months of age. The study found that children who received early measles, mumps, and rubella (MMR) vaccination before 8.5 months of age exhibited faster antibody decay and lost protective neutralizing antibody levels over six years. The research suggests that routine vaccination of infants under 8.5 months of age may lead to blunted antibody responses to subsequent MMR vaccination, and early MMR vaccination should only be considered during measles outbreaks or in situations of increased risk of measles virus infection. [Extracted from the article]

A recent study conducted by the Chinese Academy of Sciences explored the potential of a kallikrein inhibitor derived from an immunoglobulin heavy chain junction region in combating thromboinflammatory responses and stroke injury. The research highlighted the inhibitory effects of this inhibitor on plasma kallikrein activity, suggesting its promise as a therapeutic agent for thromboinflammatory conditions. The study, supported by various funding sources, concluded that this inhibitor, known as SD6, could be a valuable tool in treating such conditions without increasing bleeding risks. [Extracted from the article]

Researchers at Huazhong Agricultural University in Hubei, China, have developed a method to generate canine monoclonal antibodies that show neutralizing activity against Canine Parvovirus (CPV). This study aims to address the limitations of existing vaccines in providing comprehensive protection against CPV infection. By isolating single B cells from canine blood and expressing monoclonal antibodies, the researchers identified five antibodies with neutralizing activity against CPV, demonstrating the potential of this approach in identifying antibodies against various canine pathogens. The research was supported by the National Key Research & Development Program of China and has been peer-reviewed. [Extracted from the article]

A recent study conducted in Tehran, Iran, focused on therapeutic apheresis in pediatric renal transplant recipients. The research highlighted the effectiveness of therapeutic apheresis in managing antibody-mediated rejection, focal segmental glomerulosclerosis, and atypical hemolytic uremic syndrome in pediatric renal transplant recipients. Various modalities of therapeutic apheresis were discussed, including plasmapheresis, double filtration plasmapheresis, photopheresis, lipopheresis, and immunoadsorption. The study emphasized the importance of combining therapeutic apheresis with immunosuppressive drugs to prevent rebound phenomena and potential complications. [Extracted from the article]

A recent study conducted at Capital Medical University in Beijing, China, focused on a 7-year-old boy with immune thrombocytopenia (ITP) who developed neutralizing antibodies following treatment with recombinant human thrombopoietin (rhTPO). The boy initially showed persistent thrombocytopenia and was misdiagnosed before receiving effective treatment with rituximab (RTX) to eradicate the neutralizing antibodies. The research emphasizes the importance of monitoring antibody levels and considering antibody eradication medication in cases where the drug effect is lost. This study was peer-reviewed and published in the Annals of Hematology. [Extracted from the article]

A study conducted by Guangzhou University of Chinese Medicine focused on identifying clinical risk factors for coronary artery lesions in children with Kawasaki disease. The research, which included 260 pediatric patients, found that younger age, male gender, lower serum albumin levels, and delayed initial use of intravenous immunoglobulin were associated with a higher risk of coronary artery lesions. The study concluded that further long-term follow-up and multi-center studies are needed to validate these findings. This research was published in Cardiology in the Young and can be accessed online. [Extracted from the article]

A study conducted at Marche Polytechnic University in Ancona, Italy, explored the association between Adeno-associated Virus Type 5 (AAV5) infection via PDGFR alpha and interstitial lung disease in systemic sclerosis (SSc). The research found that AAV5 was detected in the lungs of SSc patients with interstitial lung disease and formed a molecular complex with PDGFR alpha, leading to immune responses in SSc patients. These findings provide new insights into the pathogenesis of SSc and the role of AAV5 in immune reactivity. [Extracted from the article]

Researchers at Yale University have published a report on the increasing use of bispecific antibodies (bsAbs) in biomedical imaging. These engineered antibodies target two different epitopes simultaneously, with 75% of clinically approved bsAbs entering international clinics since 2022. The study discusses the advancements in radiolabeled bsAbs for imaging in oncologic and neurodegenerative diseases, offering insights into future directions for this technology. Financial support for the research came from the National Institutes of Health (NIH) in the United States. [Extracted from the article]

A patent has been issued for a treatment of cancer using chimeric antigen receptor and a protein kinase a blocker. The invention involves immune effector cells engineered to express a CAR polypeptide that binds to a tumor antigen to treat cancer. The patent includes detailed information on nucleic acid molecules encoding the CAR and tumor antigens targeted, such as CD19, EGFRvIII, PSMA, and many others. The patent also outlines specific compositions and claims related to the treatment method. [Extracted from the article]

A study conducted at the University of Utah examined the clinical characteristics of patients with matched oligoclonal bands (OCB) from 2015 to 2020. The research found that patients with matched-only OCB were older and more likely to have a history of autoimmune disease or cancer, while those with matched + unique OCB were more likely to have specific neurological disorders. The study concluded that patients with matched-only OCB and those with matched + unique OCB have distinct clinical profiles. [Extracted from the article]

A patent has been issued for antibody variable domains targeting the NKG2D receptor by Dragonfly Therapeutics Inc. The invention focuses on antibodies that bind to NKG2D, a receptor on natural killer cells, with the potential to modulate NK cell function in therapeutic contexts, including malignancy. The patent details specific amino acid sequences and complementarity-determining regions of the antibody heavy chain variable domains, highlighting their potential in cancer immunotherapy. The method described involves administering proteins with antigen-binding sites that target NKG2D and tumor-associated antigens to treat cancer patients, utilizing the patient's immune system for targeted destruction of cancer cells. [Extracted from the article]

Researchers at Shahed University in Tehran, Iran, have developed egg yolk immunoglobulins (IgY) targeting specific proteins of Enterotoxigenic Escherichia coli (ETEC) to inhibit toxin activity and bacterial adherence. The study found that IgY antibodies against the virulence factors of ETEC showed promise in inhibiting toxin attachment and reducing fluid accumulation in the intestine. This research suggests that IgY antibodies could be used as prophylactic antibodies against ETEC bacteria. [Extracted from the article]

A patent has been issued for monoclonal antibodies, compositions, and methods for detecting complement factor D by Omeros Corporation. The invention addresses the need for detection reagents and assays to measure the presence and amount of Pro-Factor D and/or mature Factor D in biological samples. The patent describes isolated antibodies that specifically bind to epitopes on human mature Factor D and Pro-Factor D, as well as kits for detecting these proteins in test samples. The invention aims to enable in vitro assessment of APC inhibition by MASP-3 inhibitors. [Extracted from the article]

A recent study conducted at the University of Edinburgh reported a case of cryoglobulinemia associated with multiple myeloma in a 10-year-old female neutered Labrador Retriever. The dog presented with epistaxis, skin lesions, and abnormal bloodwork results, leading to a diagnosis of multiple myeloma. Despite receiving palliative care with prednisolone, the dog deteriorated rapidly and was euthanized. Cryoglobulinemia, a rare phenomenon often linked to lymphoproliferative disorders, was identified as a contributing factor to the dog's symptoms. [Extracted from the article]

A recent report from Washington University School of Medicine discusses the use of bispecific antibodies in the treatment of follicular lymphoma. Bispecific antibodies, such as mosunetuzumab and epcoritamab, have shown promising results in clinical trials, with overall response rates of approximately 80% and complete response rates of 60-70%. While these antibodies have demonstrated efficacy, they also come with safety concerns such as infections, neutropenia, and cytokine release syndrome. Ongoing studies are exploring the use of bispecific antibodies in earlier lines of treatment for follicular lymphoma, indicating their potential to improve patient outcomes in the future. [Extracted from the article]

A recent study conducted by the University of Southern Florida in St. Petersburg, Florida, focused on the quality of life in patients with primary immunodeficiency and its impact on shared decision-making and patient outcomes. The research highlighted the importance of incorporating health-related quality of life measures in clinical trials to assess changes in patients' perspectives on their disease and treatment effects. The study emphasized the significance of shared decision-making in optimizing patient care and compliance. For more information, readers can refer to the article "Quality of Life In Primary Immunodeficiency: Its Contribution To Shared Decision-making and Patient Outcomes" published in Allergy and Asthma Proceedings. [Extracted from the article]

A recent report from Sheba Medical Center in Ramat-Gan, Israel, discusses the prevalence and impact of autoimmune diseases, affecting 5 to 10% of the population. The study highlights the need for new treatments that modulate the immune system with minimal side effects. Researchers have developed a small molecule, tuftsin-phosphorylcholine (TPC), derived from helminth secretions, which showed promising immunomodulatory effects in murine models of autoimmune diseases. The findings suggest that TPC could be a novel therapy for patients with autoimmune diseases. [Extracted from the article]

A recent study from Lund University explores the potential link between constipation as a side effect of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies and poor treatment response in chronic migraine patients. The study found that constipation was more common with erenumab compared to other medications, and patients who switched treatments due to constipation experienced milder symptoms without compromising effectiveness. The researchers suggest that monitoring side effects like constipation is crucial, and further research is needed to understand the underlying mechanisms. For more information, the study can be accessed in Cephalalgia Reports published by SAGE Publishing. [Extracted from the article]

A study conducted at Zhujiang Hospital in Guangzhou, China, focused on preparing monoclonal antibodies targeting Acinetobacter baumannii to protect against multi-drug-resistant strains. The antibodies, mAb 8E6 and mAb 1B5, were found to enhance phagocytosis of A. baumannii by recognizing ATP synthase antigens, resulting in protective effects in mice against respiratory infections. This research was supported by various foundations and concluded that the antibodies significantly improved the opsonization process of phagocytosis against prevalent A. baumannii strains in southern China. [Extracted from the article]

A recent report from Yale University School of Medicine discusses the discovery of a nuclear-penetrating scleroderma autoantibody that inhibits the formation of the Topoisomerase 1 cleavage complex, which is essential for DNA nicking. This finding suggests that anti-Topoisomerase 1 autoantibodies may contribute to cellular dysfunction in diffuse cutaneous systemic sclerosis (dcSSc). The research was funded by Patrys Ltd and the Department of Therapeutic Radiology at Yale School of Medicine, and has been peer-reviewed. For more information, readers can refer to the original article in Biochemical and Biophysical Research Communications. [Extracted from the article]

Researchers at Case Western Reserve University have conducted a narrative review and perspective on the therapeutic use of monoclonal antibodies against amyloid plaques in older adults with Down Syndrome (DS). DS is a genetic disorder caused by an extra copy of chromosome 21 and is associated with an increased risk of early-onset Alzheimer's disease. The study explores the potential of using anti-amyloid monoclonal antibodies in the prevention and treatment of DS-associated Alzheimer's disease, highlighting the challenges and opportunities for research in this area. For more information, the full article can be accessed for free at the Brain Sciences journal website. [Extracted from the article]

A recent study conducted at the State University of New York (SUNY) Buffalo focused on comparing the characteristics of B cell variable gene segments in neuro-autoantibodies related to encephalitis. The research aimed to identify specific antibody signatures associated with neuroautoimmune diseases, such as N-methyl-d-aspartate receptor (NMDAR) and leucine-rich, glioma-inactivated 1 (LGI-1). The findings indicated that there is no global structural restriction on the types of autoantibodies that can cause encephalitis, with different isotypes being predominant in NMDAR and LGI-1 autoantibodies. This research contributes to a better understanding of autoimmune encephalitis, potentially improving diagnosis and treatment in the future. [Extracted from the article]

A recent study from McGill University in Montreal, Canada, focused on improving the biocompatibility of coronary stents by immobilizing fibronectin on metal surfaces such as 316L stainless steel, cobalt chromium, and nickel titanium. The research utilized polarization modulation infrared reflection adsorption spectroscopy to confirm the presence of fibronectin on the surfaces and found that the spacing between fibronectin molecules on a modified stent surface was optimal for cell/surface interactions. This study provides valuable insights into enhancing the performance of coronary stents through surface modifications. [Extracted from the article]

Researchers at the University of California San Francisco (UCSF) have conducted a study on interstitial lung diseases (ILDs) and autoimmunity. Using Phage Immunoprecipitation-Sequencing (PhIP-Seq), they identified CDHR5 autoantibodies in select patients with ILD, which may impact prognosis and treatment. The study, supported by various organizations, suggests a link between CDHR5 and autoimmunity, highlighting the importance of further research in this area. For more information, the full article is available in ACR Open Rheumatology. [Extracted from the article]

The article discusses a study on Sjogren's Disease (SjD), an autoimmune condition affecting salivary and lacrimal glands, in male NOD and NOR mice. The research focused on evaluating autoantibody profiles in serum and tears from these mice using immunofluorescence and autoantibody microarrays. The findings suggest that NOD and NOR mice with SjD-associated autoimmune dacryoadenitis have distinct autoantibody profiles in tears and serum, with tear IgA autoantibodies showing greater diversity than tear IgG autoantibodies. The presence of tertiary lymphoid structures in the lacrimal glands is believed to be a likely source of the tear autoantibodies. [Extracted from the article]

A recent study highlighted in Health & Medicine Week discusses the potential of the probiotic strain Lactococcus lactis subsp. cremoris C60 in promoting immunoglobulin A (IgA) production through the modification of dendritic cells and B cells in the intestinal environment. The strain was found to increase IgA production by modulating cytokine production in dendritic cells and promoting functional changes in B cells. This research suggests that C60 could be a promising probiotic for enhancing immune responses and maintaining intestinal immune homeostasis. The study has not yet undergone peer review. [Extracted from the article]

Researchers from the University of Colorado Anschutz Medical Campus conducted a study on rheumatoid arthritis, focusing on the presence of multiple autoantibodies before a diagnosis of the condition. The study aimed to identify an autoantibody profile that could indicate the imminent onset of clinical rheumatoid arthritis. Results showed that multiple autoantibodies are present in the pre-rheumatoid arthritis period and increase in positivity as the time of diagnosis approaches, providing insights into predicting and assessing the risk and timing of developing clinical rheumatoid arthritis. The research was supported by the Congressionally Directed Medical Research Programs and the National Institute of Arthritis And Musculoskeletal And Skin Diseases. [Extracted from the article]

A new study from Rotterdam Eye Hospital in the Netherlands introduces a novel and rapid bioassay called Turbo TSI for detecting thyroid-stimulating immunoglobulins in Graves' orbitopathy patients. The research compares the clinical performance of Turbo TSI with two commonly used immunoassays, showing that Turbo TSI has high sensitivity and negative predictive value. The study also explores the association of Turbo TSI and TBII measurements with GO activity and severity, as well as response to treatment, indicating that Turbo TSI is a strong marker of disease activity and IVMP response. [Extracted from the article]

The study conducted by F. Hoffmann-La Roche - Roche Pharma Research and Early Development focused on the modification of therapeutic T-cell bispecific monoclonal antibodies (TCB mAbs) by 5R-hydroxylysine (Hyl) and identified procollagen-lysine 2-oxoglutarate 5-dioxygenases (PLODs) as the enzymes responsible for this modification. The research utilized a hybrid LC-MS/MS molecular characterization and CRISPR/Cas9 gene deletion approach to identify and inhibit Hyl formation in TCB mAbs produced in Chinese hamster ovary (CHO) cell culture processes. The findings offer insights into addressing technical and biological challenges associated with unintended Hyl modification in therapeutic complex mAb formats. [Extracted from the article]

A study conducted at Hospital Center Baixo Vouga in Aveiro, Portugal, analyzed the clinical phenotypes of patients with anti-Ro52 and/or anti-Ro60 antibodies. The research found that anti-Ro52 antibodies were more frequently associated with non-rheumatic diseases, older age, and men, while anti-Ro60 antibodies were linked to connective tissue diseases. The study concluded that anti-Ro52 antibodies are prevalent in patients with different clinical phenotypes compared to anti-Ro60 antibodies. [Extracted from the article]

A meta-analysis conducted by researchers at Hubei University of Medicine evaluated the efficacy of azithromycin combined with intravenous immunoglobulin (IVIG) in treating refractory Mycoplasma pneumoniae pneumonia (RMPP) in children. The study included 13 randomized controlled trials and two cohort studies, totaling 1,142 children, and found that the combination treatment was more effective than azithromycin alone, resulting in higher clinical efficacy rates and shorter recovery times. The research concluded that azithromycin combined with IVIG is a more effective treatment for children with RMPP. [Extracted from the article]

A patent has been issued for an anti-BAG2 antibody by Medpacto Inc., which specifically binds to a BAG2 polypeptide involved in cancer treatment. The antibody targets the BAG2 protein, which plays a role in apoptosis, cell proliferation, and neurodegenerative diseases. This patent aims to develop an antibody that can inhibit cancer progression by targeting BAG2, potentially improving treatment outcomes for cancer patients. [Extracted from the article]

The article discusses a clinical trial, NCT06665035, focusing on the safety and effectiveness of a Tetravalent Dengue Vaccine (TDV) in children under 2 years old. The study aims to evaluate the vaccine's immunogenicity and safety by administering two doses of TDV or a placebo to children aged 6-21 months. Blood samples will be collected to assess the vaccine's impact on the immune system, with participants visiting the clinic 8 times for vaccinations, blood draws, and health checks. The trial is set to conclude on March 3, 2030, with detailed outcome measures and eligibility criteria provided. [Extracted from the article]

The patent issued by Merus N.V. focuses on methods and means for producing Ig-like molecules, specifically bispecific antibodies, to target multiple disease-modifying molecules. The patent addresses the limitations of monoclonal antibodies in treating complex diseases by proposing the use of bispecific antibodies that can bind to two different epitopes on the same or different targets. By utilizing a single molecule with two binding regions, bispecific antibodies offer a more cost-effective and efficacious alternative to traditional monoclonal antibodies. The patent outlines methods for producing heterodimeric antibodies from a single cell, emphasizing the importance of specific amino acid residues in the CH3 domain for promoting heterodimerization over homodimerization. [Extracted from the article]

A recent report from the Medical University of Vienna discusses the effectiveness of the PreS-based recombinant vaccine VVX001 in inducing hepatitis B virus neutralizing antibodies in individuals who are low-responders to HBsAg-based HBV vaccines. The study found that vaccination with VVX001 resulted in a strong and sustained antibody response, with maximal HBV neutralization achieved one month after the last injection. The research suggests that VVX001 may be a viable option for preventive vaccination against HBV, even in individuals who do not respond well to traditional HBsAg-based vaccines. [Extracted from the article]

A recent study conducted at Tianjin Medical University General Hospital in China explored the clinical value of seven autoantibodies against tumor-associated antigens and tumor markers in lung cancer patients. The research found that while the sensitivity of the autoantibodies alone was limited, combining them with tumor markers improved sensitivity and positivity, albeit at the cost of decreased specificity. The study suggests that further research is needed to assess the performance of this combined approach in cancer screening and early detection. [Extracted from the article]

A patent application titled "Targeted Delivery Of Therapeutic Enzymes" was published online by inventors from Russia. The application focuses on using therapeutic enzymes to treat lysosomal storage diseases, specifically mucopolysaccharidoses, by coupling the enzymes with a transport element to facilitate delivery through the blood-brain barrier. The compound described in the patent aims to address enzyme deficiencies in these diseases, which lead to the accumulation of carbohydrates in cells and tissues, causing various health complications. The patent outlines specific amino acid sequences and methods for treating lysosomal storage diseases with neurological components. [Extracted from the article]

A patent application titled "Combination Therapy of Immunotoxin and Checkpoint Inhibitor" has been published online, detailing a method for treating tumors by administering an immunotoxin and an immune checkpoint inhibitor. The inventors highlight the urgent need for advanced therapeutic approaches to improve the survival outlook of patients with glioblastomas and other tumors expressing EGFR receptors. The patent application provides treatment methods, regimens, kits, and agents for addressing these medical challenges. [Extracted from the article]

A patent has been issued for Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies by Novo Nordisk A/S. These antibodies aim to improve treatment for individuals with coagulopathies, such as hemophilia A or B, by binding to specific proteins involved in the blood coagulation process. The invention focuses on prolonging the circulatory half-life of Factor VIIa and stimulating its activity to enhance blood clotting. This development addresses the need for safer and more effective treatments for individuals with hemophilia, supplementing current standards of care. [Extracted from the article]

A patent has been issued for compositions and methods aimed at inhibiting the binding of plasma IGG autoantibodies to the serotonin 2A receptor. The patent, filed by Mark B. Zimering, focuses on identifying individuals at risk for developing neurodegenerative diseases through the use of decoy peptides. These peptides are designed to interact with 5-hydroxytryptamine 2A receptor autoantibodies and could potentially aid in the prevention or treatment of such diseases. The patent also outlines methods for administering these peptides to individuals with conditions like refractory hypertension, obesity, type 2 diabetes, or traumatic brain injuries. [Extracted from the article]

The article discusses a national screening program for the presence of Islet Autoantibodies (IA) in relatives of individuals with type 1 diabetes, aiming to identify pre-clinical stages of the disease and prevent Diabetic Ketoacidosis (DKA). Participants will be screened for four islet autoantibodies, and those with positive results will undergo confirmation testing. The study aims to document cases of diabetes progression and DKA events in participants with IA. The trial is observational, with a recruitment goal of 20,000 participants in Israel, aged 2-45 years, who are first-degree relatives of Type 1 Diabetes probands. [Extracted from the article]

Researchers from the "Tor Vergata" University of Rome conducted a systematic review on the use of monoclonal antibodies for treating osteoarthritis (OA) in animal models. The study analyzed 10 articles focusing on various targets, such as VEGF, NGF, IL4-10, TNF-a, ADAMTS5, and MMP-13, with most studies administering the antibodies weekly. The research concluded that monoclonal antibodies show promise in OA treatment, offering targeted approaches to modulate disease pathways, but further research and clinical trials are needed to validate their safety and efficacy. [Extracted from the article]